The proliferation and terminal differentiation of erythroid progenitors occurs in human bone marrow within erythroblastic islands, specialised structures consisting of a central macrophage surrounded by developing erythroid cells. Many cell-cell and cell-matrix adhesive interactions maintain and regulate the co-ordinated daily production of reticulocytes. Erythroid cells express only one integrin, a4b1, throughout differentiation, and its interactions with both macrophage Vascular Cell Adhesion Molecule-1 and with extracellular matrix fibronectin are critical for erythropoiesis. We observed that proerythroblasts expressed a broad tetraspanin phenotype, and investigated whether any tetraspanin could modulate integrin function. A specific association between a4b1 and CD81, CD82 and CD151 was demonstrated by confocal microscopy and co-immune precipitation. We observed that antibodies to CD81 and CD82 augmented adhesion of proerythroblasts to Vascular Cell Adhesion Molecule-1 but not to the fibronectin spliceoforms FnIII 12-IIICS-15 and FnIII 12-15 . In contrast, different anti-CD151 antibodies augmented or inhibited adhesion of proerythroblasts to Vascular Cell Adhesion Molecule-1 and the fibronectin spliceoform FnIII 12-IIICS-15 but not to FnIII 12-15 . These results strongly suggest that tetraspanins have a functional role in terminal erythropoiesis by modulating interactions of erythroblast a4b1 with both macrophages and extracellular matrix. 
Introduction
In normal human bone marrow, terminal erythroid differentiation occurs within erythroblastic islands [1] . This specialised erythropoietic niche, first described by Bessis [2] , comprises a central macrophage surrounded by adherent developing erythroblasts. Within islands, extensive cell-cell interactions occur not only between adjacent erythroblasts, but also between erythroblasts and macrophages, such that each erythroblast is in direct contact with macrophage cellular processes [3] . Some of the molecules involved in these intercellular interactions have been identified (reviewed in [1] ). These include: i) macrophage sialoadhesin (CD169, Siglec-1) binding to sialylated erythroblast glycoproteins [4] , ii) homophilic binding of Erythroblast-Macrophage Protein on both macrophages and erythroblasts [5] , iii) macrophage Vascular Cell Adhesion Molecule-1 (VCAM-1) binding to erythroblast a4b1 [6] , iv) macrophage aV integrin binding to erythroblast Intercellular Adhesion Molecule-4 [7] , and v) macrophage CD163 (receptor for haemoglobin-haptoglobin complexes) binding to an unidentified erythroblast receptor [8] .
The importance of a4b1 during erythropoiesis, and of erythroblast a4b1 interactions with macrophage VCAM-1 has been extensively studied. In vivo administration of anti-a4 antibody rendered mice anaemic [9] , while in vitro addition of antibodies reactive with anti-a4 or anti-VCAM-1 antibodies reduced stromal cell-dependent erythropoiesis [10] and disrupted erythroblastic island integrity [6] . Additionally, a requirement for appropriately activated a4b1 for the in vitro reformation of erythroblastic islands has also recently been demonstrated in SWAP-70-deficient mice [11] . SWAP-70, a protein involved in integrin regulation and cytoskeletal F-actin rearrangement, affects development of erythroid progenitors in bone marrow and spleen by negative regulation of a4b1 [11] . In normal human bone marrow, a4b1 is clustered at contact sites between macrophages and erythroblasts [12] , and this heterophilic cell contact enhances proliferation [5, 13, 14] . A role for a4b1 in the optimal expansion and differentiation of erythroid cells in bone marrow, rather than an absolute requirement of a4b1 in erythropoiesis was also evident in a4-null chimeric mice [15] . Studies of the effects on erythropoiesis of a4, b1 or VCAM-1 deficiencies in different mouse models have yielded conflicting results, and demonstrated different effects in bone marrow and splenic erythropoiesis [15] [16] [17] [18] [19] [20] . However while conditional knockout mice were not anaemic, a role for a4 and b1 but not for VCAM-1 has been demonstrated in stress erythropoiesis with defects in erythroid progenitor expansion in bone marrow and/or spleen, and in cell maturation [11, [18] [19] [20] .
The continued expression of a4b1, the only integrin expressed throughout terminal erythroid maturation [21, 22] , suggests that interactions within erythroblastic islands between erythroblast a4b1 and its ligands, macrophage VCAM-1 and fibronectin [23] , are both important for effective erythropoiesis. The early erythroid progenitors, BFU-E and CFU-E, and preproerythroblasts, adhere to fibronectin via both integrins a4b1 and a5b1 [21, 24, 25] . Whereas a5b1 expression is lost on basophilic erythroblasts, the continued expression but progressive down-regulation of a4b1 during terminal maturation is accompanied by a progressive decrease in attachment to fibronectin until the reticulocyte stage, where these cells are non-adherent [25] . While fibronectin has only one binding site for a5b1, there are five sites for a4b1, three in alternatively spliced regions [26] . The temporal expression of a4b1 and a5b1 during differentiation and the complex expression of fibronectin spliceoforms in adult bone marrow [27] hint at distinct and stage-specific functions for integrin/fibronectin interactions during erythroid proliferation and differentiation. Indeed, fetal liver erythroblast a4b1 interaction with fibronectin is essential for maximal erythroid expansion [28] . The appropriate activation state of a4b1 is also important for a4b1-fibronectin interactions since SWAP-70-deficient CFU-E hyper-adhere to fibronectin in vitro [11] .
Many membrane proteins, including integrins, are components of multi-molecular complexes that together regulate their interactions and functions [29] [30] [31] [32] . It has recently been suggested that erythroblast membrane proteins may also associate in complexes [14] since antibodies to any one protein disrupts macrophageerythroblast interactions and island integrity [4, [6] [7] [8] 33] . Integrins, including a4b1, are found in complexes with tetraspanins in various cell types [29, 34] . The tetraspanins are a large family of small, widely expressed cell surface proteins that interact with a broad range of proteins such as other tetraspanins, integrins, Immunoglobulin Superfamily proteins and other adhesion molecules, ectoenzymes and intracellular signalling molecules [35, 36] . Tetraspanins associate through lateral interactions with other tetraspanins and membrane proteins to form tetraspanin-enriched microdomains [36] . By organising multimolecular membrane complexes they regulate many cellular processes including modulating ligand binding, adhesion strengthening, cell migration, proliferation, cell fusion and signalling events [35] [36] [37] [38] . Tetraspanins also localize to intracellular vesicles, suggesting a role in protein trafficking [29] . The observations that tetraspanins CD81 (Target of Anti-Proliferative Activity-1) and CD151 (PlateletEndothelial Tetra-span Antigen-3) are associated with a4b1 and can augment cell adhesion to fibronectin in erythroleukemic cells [39] [40] [41] led us to investigate the hypothesis that tetraspanins were also associated with a4b1 in primary erythroblasts and could play a role in erythropoiesis by regulating erythroblast a4b1 interactions with macrophage VCAM-1 and/or fibronectin.
This report describes the first complete tetraspanin profile of human erythroblasts derived in vitro from peripheral blood CD34+ progenitors in suspension culture. We show that erythroblasts express several tetraspanins found on other haematopoietic cells and continue to express CD81, CD82 and CD151 on terminally differentiating cells. Focusing on three stages of late maturation, the proerythroblast, basophilic erythroblast and polychromatic erythroblast, we demonstrate a physical and functional association between CD81, CD82 and CD151 with a4b1 by confocal microscopy, co-immune precipitation and cell attachment assays to a4b1 ligands, VCAM-1 and fibronectin. We show that from the proerythroblast through to later stages of erythroid maturation a proportion of plasma membrane a4b1 molecules are associated with both CD81-and CD82-enriched microdomains, and that CD81 and CD82 associate with each other. Furthermore, antibodies to both CD81 and CD82 augment proerythroblast attachment to VCAM-1, but have little effect on more mature cells, or on attachment to fibronectin spliceoforms, FnIII 12-IIICS-15 (H/120) and FnIII [12] [13] [14] [15] (H/0). CD151 also associates with a4b1 but anti-CD151 could either augment or inhibit proerythroblast adhesion to both VCAM-1 and fibronectin spliceoform H/120, but not to H/0. These data strongly suggest that CD81, CD82 and CD151 play an important role during erythropoiesis by modulating the adhesive properties of a4b1.
Materials and Methods

Ethics Statement
Buffy coats, a waste fraction from anonymous donations of platelets by apheresis, were provided with written informed consent for research use in accordance with both the Declaration of Helsinki and with the policy of the National Health Service Blood and Transplant. The research into the mechanisms of in vitro erythropoiesis was reviewed and approved by the Southmead Local Research Ethics Committee 08/05/2008 REC number 08/H0102/26.
All reagents, tissue culture media, growth factors, cytokines and certain antibodies were purchased from Sigma (Poole, Dorset, UK) unless stated otherwise.
Erythroid Cultures
Human CD34+ haematopoietic progenitor cells were isolated from human blood donor mononuclear cells (waste buffy coats, see Ethics Statement) by positive selection using the MiniMACS magnetic bead system (Miltenyl Biotech, Bisley, UK) as described by the manufacturer's protocol. The isolated CD34+ cells were pooled and cultured at 37uC in a humidified atmosphere of 5% CO 2 in air in a 2-stage protocol to induce differentiation along the erythroid lineage following a modified method of Griffiths et al. [42] . CD34+ cells were seeded at 1.5610 5 /ml in primary medium and maintained at 2610 5 /ml after day 3. When the first glycophorin A (GPA)-positive cells appeared (days 5-6) erythroblasts were harvested, washed thrice in Hanks Balanced Salt solution and seeded into secondary culture medium and maintained at 3-8610 5 /ml. Protocol A used Iscove's Modified Dulbecco Medium (IMDM) containing 1% (w/v) bovine serum albumin (BSA), 10 mg/ml recombinant human insulin and 200 mg/ml iron saturated human transferrin (''Stemspan SFEM'', Stemcell Technologies SARL). In the first stage of culture (day 0-5 or 6) the IMDM was supplemented with 10 ng/ml recombinant human (rH) Stem Cell Factor (SCF, R & D Systems Europe, Abingdon, Oxfordshire, UK), 3 U/ml Erythropoietin (Epo, Roche Products, Welwyn Garden City, UK), 1 ng/ml rH Interleukin-3 (IL-3, R & D Systems Europe), 1 ml/ml cholesterol-rich lipid mix, 0.1 ng/ml Prograf (Fuisawa, Killorglin, Ireland) and 1 U/ml penicillin and streptomycin. In the second stage (days 5-6 onwards) the primary medium was replaced with Stemspan SFEM supplemented with additional 800 mg/ml iron saturated human transferrin, 3% v/v heat inactivated human male group AB serum, 10 U/ml Epo, 10 ng/ml insulin, 1 mM tri-iodothyroxine and 1 U/ml penicillin and streptomycin. Protocol B primary culture medium (days 0-5) comprised IMDM (Source BioScience) containing 3% male AB serum, 2% foetal bovine serum (Hyclone, Fisher Scientific UK Ltd), 200 mg/ml iron-saturated transferrin, 10 ng/ml SCF, 3 U/ml Epo, 1 ng/ml IL-3, 0.1 ng/ml Prograf and 1 U/ml penicillin and streptomycin. Secondary stage medium (day 5 onwards) comprised IMDM, 3% male AB serum, 2% foetal bovine serum, 300 mg/ml iron-saturated transferrin, 3 U/ml Epo, 10 ng/ml insulin, 0.1 ng/ml Prograf and 1 U/ml penicillin and streptomycin. Cultures grown in Protocol B media showed increased proliferation over those grown in Protocol A media.
HEL Cell Line
The human erythroleukemia line, HEL, (ECACC, Salisbury, Wiltshire, UK) was maintained at 3610 5 /ml in Iscove's Modified Dulbecco's Medium (IMDM, PAA, Laboratories GmbH, Pasching, Austria) containing 10% foetal bovine serum (Fetal Clone 1, HyClone, Logan, Utah) at 37uC in a 5% CO 2 atmosphere.
Flow Cytometry
Antigen expression was analyzed by flow cytometry as described [43] ; antibodies used are listed in Table 1 . RPE-conjugated isotype negative control antibodies were from eBioscience Ltd (Hatfield, Hertfordshire, UK) and BioLegend UK Ltd (Cambridge, Cambridgeshire, UK). Secondary antibody RPE F(ab') 2 goat antimouse IgG Fc-specifc was from Dako Cytomation (Glossop, UK). After labelling the cells were fixed in phosphate buffered saline (PBS) containing 1% (v/v) BSA (Lorne Laboratories, Reading, Berkshire, UK) and 1% w/v paraformaldehyde then analysed on a FC500 flow cytometer using Kaluza software (Beckman Coulter (UK) Ltd, High Wycombe, Buckinghamshire, UK).
Confocal Microscopy
Cells (3610 5 cells per coverslip) were seeded on 0.01% (w/v) poly-L-lysine coated coverslips and incubated for 30 minutes at 37uC in 5% CO 2 . Cells harvested from culture on days 5 to 10 were fixed with 3% paraformaldehyde (TAAB, Aldermaston, UK) for 20 minutes and permeabilised with 0.05% (w/v) digitonin (Merck Millipore, Beeston, Nottinghamshire, UK) for 5 minutes, then incubated for 15 minutes in 4% BSA (Park Scientific, Northampton, Northamptonshire, UK). Subsequent washes were carried out in PBS. Cells harvested from culture from day 11 onwards were fixed in 1% paraformaldehyde and permeabilised in 0.05% saponin (Merck Millipore). Subsequent washes and antibody dilutions were carried out in PBS containing 0.005% saponin, 5 mg/ml BSA and 1 mg/ml glucose. When dual labelling with two monoclonal primary antibodies the first antibody was subjected to an extra conversion step by the addition of AffiniPure Fab fragment rabbit anti-mouse IgG (Jackson ImmunoResearch, Stratech Scientific Ltd, Newmarket, Suffolk, UK) at a concentration of 1/20 in 4% BSA. After this conversion step the second monoclonal antibody was added. Primary antibodies used are listed in Table 1 . Goat anti-mouse Alexa fluorH 488 or goat anti-rabbit Alexa fluorH 546 (Invitrogen, Carlsbad, California, USA) conjugated secondary antibodies were diluted in 4% normal goat serum and incubated with the cells for 30 minutes at room temperature in the dark. Coverslips were mounted on VectashieldH Mounting Medium (Vector Laboratories, Burlingame, California, USA) on microscope slides and sealed with nail varnish. Samples were imaged at 22uC using 406 oil immersion lenses (magnification = 101.97 mm at zoom 3.8, numerical aperture 1.25) on a Leica SP5 confocal imaging system. Images were obtained using Leica software and subsequently processed using Adobe Photoshop.
Immune Precipitation, SDS-PAGE and Immunoblotting
Cells were washed thrice in 10 mM Tris, 150 mM NaCl, pH 7.4 (TBS), containing either 2 mM ethylenediaminetetraacetic acid (EDTA), 1 mM CaCl 2 plus 1 mM MgCl 2 or 1 mM MnCl 2 (TBS +/2 cations/EDTA) by centrifugation at 400 g for 5 mins at 4uC. The cell pellet was lysed for 25 mins on ice in lysis buffer (TBS +/2 cations or 2 mM EDTA, 1% (w/v) polyoxyethylene (10) oleyl ether (Brij-97), 2 mM phenyl methyl sulphonyl fluoride (PMSF) and EDTA-free protease inhibitor cocktail (Complete TM , Roche Diagnostic GmbH, Mannheim, Germany). In some experiments polyoxyethylene (20) oleyl ether (Brij-99), Triton X-100 (TX-100), Nonidet P40 (NP40) or 3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulphonate hydrate (CHAPS) were also used at 1% w/v in place of Brij-97. Cells were solubilised at 10 7 /ml for HEL cells and proerythroblasts (days 5-6 of culture), 1.5610 7 /ml for basophilic erythroblasts (days 7-8 of culture) and 3610 7 /ml for polychromatic erythroblasts (days 11-12 of culture), centrifuged at 208,000 g for 30 mins at 4uC and the supernatants were stored at 280uC. Immune precipitates were isolated from the cell lysates with antibodies (see Table 2 ) pre-coupled to Protein G Sepharose 4 Fast Flow (PGS, GE Healthcare Life Sciences, Little Chalfont, Buckinghamshire, UK) after an initial pre-clearing step with Protein G-coupled isotype control antibodies [40] . Immune complexes were eluted into non-reduced sample buffer [44] containing 2 mM PMSF and EDTA-free protease inhibitor cocktail. Samples were run on 7.5% or 12% (w/v) non-reduced polyacrylamide gels. Immunoblotting under semi-dry transfer conditions was as described [7] except that PVDF membranes (Millipore UK Ltd, Watford, Hertfordshire, UK) were blocked with PBS containing 0.8% v/v Tween-20 and 5% w/v c-globulinfree BSA fraction V. Biotinylated antibodies to CD81 (clone 1.3.3.2, Alexis Corporation, Enzo Life Sciences (UK) Ltd, Exeter, Devon, UK) and rabbit anti-sera to a5, b1, b2 and b3 (R&D Systems, Abingdon, Oxfordshire, UK) were used. Rabbit monoclonal anti-a4 antibody was from Cambridge Bioscience (Cambridge, Cambridgeshire, UK), polyclonal anti-CD82 antibody was from AbCam (Cambridge, Cambridgeshire, UK) and anti-CD53 (MEM-53), anti-CD63 (MEM-259) and anti-CD151 (IIG5a) antibodies were from AbD Serotec. Secondary reagents were streptavidin-alkaline phosphatase conjugate (Perkin Elmer, Cambridge, Cambridgeshire, UK) and alkaline phosphatase-conjugated F(ab') 2 fragments of goat anti-sera to rabbit and mouse IgG (Jackson ImmunoResearch). Membranes were developed with Western Lightning CDP Star Chemiluminescent Reagent (Perkin Elmer) and images were recorded on a Kodak imager using Kodak imaging software.
Fusion Proteins
7-domain Vascular Cell Adhesion Molecule-1-Fc fusion protein (VCAM-Fc) was purchased from R&D Systems. Human fibronectin constructs FnIII [12] [13] [14] [15] (H/0) and FnIII 12-IIICS-15 (H/120), in the pGEX expression vector, were a kind gift from Prof. M. Humphries (University of Manchester) [45] . The constructs were transformed into Rosetta 2(DE3) pLysS E. coli cells (Novagen, Merck Millipore) for expression as previously described [46] . In brief, 10 ml Luria-Bertani (LB) broth cultures with 50 mg/ml carbenicillin and 35 mg/ml chloramphenicol, were inoculated from a glycerol stock and grown overnight at 37uC. 1 L of LB media was inoculated and grown to OD600 = 0.6. Protein expression was induced by addition of 1 mM isopropyl b-D-1-thiogalactopyranoside at 20uC for 16 h. Cells were harvested by centrifugation, the cell pellet was resuspended in buffer A (50 mM tris pH 8, 150 mM NaCl) supplemented with a protease inhibitor tablet (Roche Diagnostics) and DNAseI. The protein was released by sonication and the insoluble fraction pelleted by centrifugation. The supernatant was loaded onto a 5 mL GSTrap FF column (GE Healthcare, Little Chalfont, Buckinghamshire, UK) pre-equilibrated with buffer A. Recombinant protein was eluted by an increasing gradient of buffer B (50 mM tris pH 8, 150 mM NaCl and 10 mM reduced glutathione). The protein was further purified by gel filtration on a HiLoad 16/60 superdex 200 (GE Healthcare) equilibrated in buffer A. Pooled recombinant protein fractions were analysed by SDS-PAGE for .95% purity and confirmed by N-terminal sequencing and mass-spectrometry. Liberation of recombinant human fibronectin H/0 from the glutathione synthase (GST)-tag was accomplished by incubation at 4uC for 20 h with 25 U thrombin. The sample was applied to a GSTrap FF column and benzamidine column (GE Healthcare) in tandem to remove cleaved GST-tag, uncleaved protein and thrombin. Cleaved recombinant H/0 was further purified by gel filtration as above.
Cell Adhesion Assays
Attachment assays were performed essentially as described [47] with modifications. Immulon-4 HBX 96 well plates (Dynex Technologies, Billingshurst, UK) were coated with either 1 mg/ ml goat anti-human Fc or anti-GST antibody (AbCam) in bicarbonate buffer overnight at 4uC then incubated with either Fc-or GST-fusion proteins as appropriate overnight at 4uC.
Fibronectin H/0 fragment without the GST tag was coated directly onto the plates in PBS. Plates were blocked with PBS containing 4% fraction V BSA. Media for fluorescently labelling cells were either RPMI1640 containing 0.1% BSA (RPMI LB) or IMDM containing 0.1% BSA and 2 mM ethylene glycol tetracetic acid (IMDM LB). Activation of cells with 80 mM phorbol myristate acetate (PMA) was performed at the same time as fluorescence labelling in IMDM LB. Cells were washed after labelling in either RPMI LB or IMDM LB supplemented with additional CaCl 2 plus MgCl 2 to 1 mM of each, or with 1 mM MnCl 2 or 10 mM MgCl 2 (assay buffers, AB). Fluorescently labelled cells in AB were added at 2610 5 /well for proerythroblasts (day 5 of culture), 2.5610 5 /well for basophilic erythroblasts (days 7/8 of culture) and 3610 5 /well for polychromatic erythroblasts (day 11-12 of culture). Titration assays had 4 replicates per dilution while 6 replicates were used in antibody activation/ inhibition assays. For the latter assays, cells were incubated for 15 mins at room temperature in AB containing 10 mg/ml antibodies before addition to the plates. The plates were coated with proteins at a concentration where just less than maximal cell attachment was obtained. The statistical software package, SigmaPlot12, was used for the one way analysis of variation of results of adhesion assays performed in the presence of added antibodies. 
Results
Tetraspanin and Integrin Expression during Erythropoiesis
In our 2-stage cultures 100% of cells expressed the Kell glycoprotein (Kell) by day 3, glycophorin A (GPA) first appeared about day 5 while the erythroid anion exchanger-1 (AE1) was expressed after day 7 ( Figure 1A) , consistent with the temporal expression of these proteins [48] . The cultures were synchronous at day 5 comprising 90-95% proerythroblasts, predominantly (80%) basophilic erythroblasts on day 8, and and a mixed population of polychromatic and orthochromatic erythroblasts, with a minority of reticulocytes and free nuclei by day 12 ( Figure 1A) . We looked at the expression of 7 haematopoietic tetraspanins in these cultures and observed that from day 3, when all cells expressed Kell, until the first appearance of GPA (around day 5), approximately 45% of cells expressed CD9 whereas all cells were positive for CD37, CD53, CD63, CD81, CD82 and CD151. This tetraspanin profile is similar to that reported for CD34+ cells and the leukaemic proerythroblast cell line, HEL [49, 50] . At later stages of maturation, CD9 was down-regulated first (almost negative by day 8, basophilic erythroblasts), followed by CD37 and CD53 (negative by day 12, polychromatic erythroblasts), and lastly, CD63 and CD81 (weaker expression by day 12). CD82 and CD151 were still expressed on day 12, consistent with their continued expression at low levels on mature erythrocytes [51, 52] . Throughout erythroid maturation CD82, and to a lesser extent CD81, consistently showed the highest levels of expression of all tetraspanins. Erythroblasts also showed developmentally regulated expression of 4 integrins ( Figure 1B) , consistent with previous reports [21, 22, 53] . High levels of a4 were found throughout the culture period (days 3-12), with lower levels of a5, aL and aIIb at the early stages of culture (days 3-5). There was no or very weak expression of aV or other b1 family integrins after day 5 (data not shown). It is interesting to note that early GPA-negative erythroid cells (pre-proerythroblasts and proerythroblasts) express four integrins (a4, a5, aL and aIIb) and their full complement of 7 tetraspanins (CD9, CD37, CD53, CD63, CD81, CD82 and CD151) while more mature GPA+ erythroblasts express CD81, CD82, CD151 and a4b1 and downregulate expression of other tetraspanins and integrins. 
To explore whether CD81 and/or CD82 associate with a4b1 during erythropoiesis, we performed dual immunofluorescence staining of a4 and b1 subunits with these tetraspanins at 3 time points during terminal differentiation (days 5, 8 and 12, proerythroblasts to reticulocytes). We also examined colocalisation with CD63, which is not reported to be associated with a4b1 but is found released in exosomes with a4b1, and with CD151 which is expressed on red cells [51] . CD151 was not pursued as the antibody clone was poor by immunofluorescence and only showed internal staining on day 6 ( Figure S1 ) and became progressively weaker as the cells matured (data not shown). a4 colocalised with b1 at the cell surface at all 3 time points, although the distribution of colocalisation changed as the cells matured (Figure 2A ). On day 5 (proerythroblasts), a4 and b1 were present together in small discrete microdomains; by day 8 (basophilic erythroblasts) these areas of colocalisation appeared to coalesce into larger aggregates less evenly spread over the cell surface; by day 12 (polychromatic and orthochromatic erythroblasts) these large aggregates were still evident with weaker staining on reticulocytes (Figure 2A ). Tetraspanins CD81 and CD82 followed this pattern of cell surface colocalisation with both a4 and b1, with fewer but larger microdomains apparent as the cells matured (Figure 2A) . By day 12, there was a heterogenous population of enucleating erythroblasts and reticulocytes present (Figure 3 ). CD81 and CD82 continued to colocalise with both a4 and b1 in late nucleated erythroblasts in a few large vesicles ( Figure 3A) . The coalescence of the integrinand tetraspanin-containing vesicles was even more apparent after enucleation, with staining present in a few large vesicles in reticulocytes, with CD82 staining more abundant than CD81 ( Figure 3B ). Only at the reticulocyte stage was CD63 also found colocalised at the cell surface with both a4 and b1 on day 12, although usually in one large vesicle ( Figure 3B ). We hypothesise that these a4b1-positive vesicles coated with CD63, CD81 and CD82 are about to be released from early reticulocytes as exosomes [42] , resulting in the loss of the majority of CD63, CD81 and a4b1 and a proportion of CD82. This is consistent with the removal of murine b1 by the exosome pathway [54] and findings that low levels of CD82 but not a4b1, CD63 or CD81 are present on mature erythrocytes [52] .
We also observed some colocalisation of CD81 and CD82 in small discrete and unevenly distributed cell surface microdomains in day 6 proerythroblasts ( Figure 2B ). This pattern of colocalisation differed from the more even distribution of the a4b1-CD81 and a4b1-CD82 complexes described above. Interestingly, colocalisation of CD81 with CD82 was particularly evident at areas of cell contact, suggesting the involvement of tetraspanins in intererythroblast interactions within erythroblastic islands.
CD81, CD82 and CD151 Coprecipitate a4b1 and aIIbb from Erythroblasts
Preliminary experiments with the leukemic proerythroblast cell line, HEL, showed the optimum conditions for coprecipitation of b1 by anti-CD81, anti-CD82 and anti-CD151 antibodies occurred after solubilisation in Brij-97 with Mn 2+ ( Figure S2 ) and subsequent experiments with primary cells used this detergent. Antibodies to the three tetraspanins co-precipitated both a4 and b1 from proerythroblasts (ProEB, day 5) and basophilic erythroblasts (BasoEB, day 8), and more weakly from polychromatic erythroblasts (PolyEB, day 12, Figure 4A ). Only the mature fully glycosylated integrins were co-precipitated by the anti-tetraspanin antibodies; both immature and mature glycosylated a4 was evident in control samples. b3 integrin was also co-precipitated by the three anti-tetraspanin-specific antibodies from b3-expressing cells (proerythroblasts and basophilic erythroblasts). Since basophilic erythroblasts expressed very little aIIb, most of the integrin may be from an intracellular pool rather than a cell surface expressed pool. All anti-CD81 (1D6, JS81, 1.3.3.2 and 454720), anti-CD82 (TS82b, 53H5, ASL-24, 423524 and B-L2) and anti-CD151 (IIG5a, 50-6 and 210127) co-precipitated a4b1 and b3 from normal and leukemic proerythroblasts ( Figure S3 A-C) . Good co-precipitation of b1 and b3 integrins by anti-CD81 and anti-CD82 antibodies and of b3 by anti-CD151 antibodies was only observed when cells were activated by Mn 2+ (Figure 4B, S4) . The b3 signal intensity was very strong in HEL, correlating with high expression of aVb3 and aIIbb3 in this cell line (Figures S2-S4) . In contrast, co-precipitation of b1 by anti-CD151 antibodies was cation independent (Figure 4B , ProEB; Figure S4 ), suggesting a stronger association of a4b1 with CD151 than with other tetraspanins. The association of a4b1 with tetraspanins CD81, CD82 and CD151 was a specific interaction since anti-CD53 and anti-CD63 antibodies did not co-precipitate b1 after activation with Mn 2+ and only co-precipitated b3 well in physiological concentrations of Ca 2+ and Mg 2+ ( Figure 4B ). Sequential probing of immunoblots of CD81 and CD82 precipitates from proerythroblasts with antibodies to a5b1, b3 and b2 clearly demonstrated the specific association between tetraspanins CD81 and CD82 and with b1 and b3 integrins and little or no association with a5 or b2 integrins ( Figure 4C ). In addition to their association with integrins, tetraspanins also associate with each other [37] , so we explored the CD81-CD82 association and its cation dependency. We observed a stronger association between CD81 and CD82 in the presence of Mn 2+ when compared with Ca 2+ and Mg 2+ in primary proerythroblasts ( Figure 4D , ProEB). HEL cells differed somewhat in that any cation supported reciprocal co-precipitation of CD81 and CD82 ( Figure 4D, HEL) . These precipitation data reinforce the confocal studies described above, and clearly demonstrate the association of tetraspanins CD81 and CD82 with one another, and with activated a4b1 during terminal erythroid maturation. We also showed a very strong association between CD151 and a4b1 throughout maturation, and a strong association of CD81, CD82 and CD151 with b3 integrins in HEL cells and in primary proerythroblasts and basophilic erythroblasts.
Vascular Cell Adhesion Molecule-1 and Fibronectin Fragment FnIII 12-CSIII-15 are High Affinity Ligands for a4b1 while Binding to Low Affinity Fibronectin Fragment FnIII 12-15 is Optimal in Activated Basophilic Erythroblasts
To explore the interaction of a4b1 with VCAM-1 and fibronectin throughout terminal maturation, we performed static adhesion assays using several different integrin activating conditions. The 7-domain VCAM-1 construct contains two a4b1-binding sites, in domains one and four. We used two fibronectin spliceoforms found in human bone marrow [27] , FnIII [12] [13] [14] [15] (H/0) and FnIII 12-CSIII-15 (H/120). H/0 is the lowest affinity ligand for a4b1 [55] and consists of a PRARI motif in the B-C loop of domain 14 [45] . H/120 has three a4b1 attachment sites, the PRARI motif and two sites in the complete alternatively spliced IIICS domain, inserted between domains 14 and 15 [26] . Within this IIICS domain the highest affinity site in the CS1 region comprises the LDV motif, while the REDV motif in the CS5 region has a lower affinity for a4b1. VCAM-1 supported high levels of cell attachment at a 10-fold lower coating concentration than H/120 and H/0 under all activating conditions at the three time points ( Figure 5 ) suggesting that VCAM-1 was the highest affinity ligand for erythroblasts at all stages of maturation. H/120 also supported similarly high maximal levels of cell attachment at all stages of maturation. The lowest levels of adhesion to both VCAM- 1 . H/0, when captured as a GST-fusion protein, did not support erythroblast adhesion at any time point (data not shown) although low levels of attachment were evident when the protein without the GST tag (pure H/0) was coated directly onto the plate ( Figure 5 ). This suggests that a specific conformation of H/0 is required for cell attachment, which is not maintained in the H/0-GST fragment. While pure H/0 did not support more than 20% of input cell binding under any activating conditions at the proerythroblast and polychromatic stages (days 5 and 11), different results were again obtained with basophilic stage cells (day 7). Although activation by PMA plus Mg 2+ had a minor effect on cell attachment, Mn 2+ greatly increased the binding affinity of basophilic cells to pure H/0. The diverse effects of the different integrin activation conditions on basophilic erythroblast attachment to the three a4b1 ligands strongly suggests that the integrin undergoes developmentally regulated changes that alter its ligand binding profile during terminal maturation. Using static adhesion assays we investigated whether adhesion of erythroblasts to VCAM-1, H/120 and H/0 in physiological concentrations of Ca 2+ with Mg 2+ was affected by antitetraspanin antibodies. Attachment to both VCAM-1 and H/ 120 was augmented by 108-127% in the presence of the b1-activating mAb, TS2/16, and was lowest on basophilic erythroblasts (118% and 108% respectively, BasoEB, Figure 6 ). Adhesion to both ligands was inhibited to a certain degree by the anti-b1-inhibitory mab 13 antibody at the 3 time points tested although inhibition was less marked on basophilic erythroblasts, and more effective against VCAM-1 than against H/120 (93%, 82% and 93% inhibition as compared to 54%, 18% and 54% inhibition, respectively, Figures 6, S5, S6 ). Neither anti-b1 antibody affected the low levels of attachment to H/0 in the presence of Ca 2+ and Mg 2+ at any time point from day 6 proerythroblasts (ProEB) solubilised in the presence of EDTA or different cations, and from Mn 2+ -activated basophilic erythroblasts (BasoEB, day 8) were probed with a mix of antibodies to a5, b1, b2 and b3 integrins while the control samples were probed with the relevant tetraspanin antibodies. For clarity, integrin controls are illustrated for the EDTA blot but were present on all blots. b1 and b3 integrins were precipitated well only in the presence of Mn 2+ . C. CD81 and CD82 precipitates from day 5 proerythroblasts were successively probed with different anti-integrin subunit antibodies and demonstrate co-precipitation of b1 and b3 but not a5 or b2 integrins. D. CD81 (454720) and CD82 (53H5) precipitates from day 6 proerythroblasts (ProEB) and HEL cells (HEL) solubilised in the presence of EDTA, Ca 2+ +Mg 2+ or Mn 2+ probed with anti-CD82 and anti-CD81 antibodies. Each tetraspanin co-precipitates the other most strongly in the presence of Mn 2+ from proerythroblasts while any cation permits co-precipitation in HEL cells. Integrins were analysed on 7.5% gels, tetraspanins on 12% gels; non-reducing conditions. Unless stated, the following clones were used: CD53, MEM-53; CD63, MEM-259; CD81, 454720; CD82, TS82b; CD151, IIG5a; a4, HP2/1; a5, IIA1; aL, TS1/22; aIIb, PAB-1. All day 5 and 6 cultures comprised 90-95% proerythroblasts; day 8 culture comprised 5% proerythroblasts, 81% basophilic erythroblasts and 14% polychromatic erythroblasts; day 12 culture comprised 41% polychromatic erythroblasts, 15% orthochromatic erythroblasts and 41% reticulocytes. In the day 5 and 6 cultures 15-34% of cells were GPA+ and 28-35% of cells were aIIb+. Day 8 and day 12 cultures had 77% and 97% GPA+ cells, respectively, and 9% and 0% aIIb+ cells, respectively. doi:10.1371/journal.pone.0062654.g004 . Day 5 cells (proerythroblasts, ProEB) were from one culture while days 7 (basophilic erythroblasts, BasoEB) and 11 (polychromatic erythrobalsts, PolyEB) cells were from a second culture which was also used for the assays depicted in (Fig. 6) (data not shown), despite evidence for increased integrin affinity induced by Mn 2+ at the basophilic stage (BasoEB, figure 5 ). Two anti-CD82 antibodies (423524 and TS82) and the anti-CD81 antibody 1D6 (epitope A), but not other anti-CD81 antibodies (JS81 [epitope B] and 454720) augmented proerythroblast adhesion to VCAM-1 by 115-125%, a similar level to that seen for the activating anti-b1 antibody ( Figure 6 , ProEB, Figure S5 and data not shown). In contrast, no anti-CD81 or anti-CD82 antibody had any effect on erythroblast adhesion to H/120 or H/0 at any stage of maturation (H/120, Figures 6, S6; H/0 data not shown). We also observed effects with anti-CD151 antibodies on adhesion to VCAM-1 and H/120 but not to H/0. The functional clone, 50-6, augmented proerythroblast but not more mature erythroblast adhesion to both VCAM-1 and H/120, whilst a minor inhibitory effect on VCAM-1 binding was also seen with IIG5a at all stages of erythroid maturation ( Figures 6, S5, S6 ). Other anti-tetraspanin antibodies to CD151 (210127), CD37 (MNM46), CD53 (63-5A3) and CD63 (TEA3/18, MEM-259) had minimal effects on adhesion to VCAM-1, H/120 or H/0 at any time point (Figure 6 and data not shown).
Discussion
Our report is the first detailed description of the tetraspanin profile of primary human erythroblasts. Proerythroblasts expressed seven tetraspanins concomitantly with four integrins, while more differentiated cells expressed only a4b1 together with tetraspanins CD81, CD82 and CD151, all of which are known to associate with a4b1 in other hemopoietic cells, including CD34+ and HEL cells [39] [40] [41] 56, 57] . Confocal imaging demonstrated the cell surface colocalisation of discrete pools of a4b1 with both CD81 and CD82, and of CD81 with CD82 throughout differentiation. The distribution of the cell surface a4b1-CD81-CD82 microdomains changed with increasing erythroblast maturation, suggesting a reorganisation of proteins within the plasma membrane. As the cells matured these complexes appeared to amalgamate, becoming fewer but larger in size. Evidence for an a4b1-CD81-CD82 complex throughout late stage maturation was also demonstrated by co-precipitation. Protein association was dependent on the presence of divalent cations, particularly Mn 2+ , an observation not reported for other cells [39, 58, 59] . Our data The pre-coating concentrations of VCAM-1 and H/120 allowed slightly less than maximal cell attachment. VCAM-1 was precoated at 0.2 mg/ml, 0.125 mg/ml and 0.25 mg/ml while H/120 was pre-coated at 2 mg/ml, 1.25 mg/ml and 1 mg/ml for proerythroblasts (ProEB, black bars, day 5), basophilic erythroblasts (BasoEB, grey bars, day 8) and polychromatic erythroblasts (PolyEB, white bars, day 12) respectively. Readings in excess of 100% input cells bound were sometimes evident in haemoglobinised cells (days 8 and 12). High levels of haemoglobin within the cells quenches the fluorescence of the initial 100% input cells bound reading, and was evident only with day 12 cells in this assay (all the H/120 results and only the VCAM-1 with TS2/16 result); this artefact does not occur with non-haemoglobinised day 5 cells. Day 5 culture comprised 5% preproerythroblasts, 91% proerythroblasts and 4% basophilic erythroblasts (28% GPA+); day 8 culture comprised 11% proerythroblasts, 60% basophilic erythroblasts and 28% polychromatic erythroblasts (88% GPA+); day 12 culture comprised 15% basophilic erythroblasts, 48% polychromatic erythroblasts, 15% orthochromatic erythroblasts and 21% reticulocytes (99% GPA+). doi:10.1371/journal.pone. 0062654.g006 suggest that more stable a4b1-CD81-CD82 microdomains assemble when erythroblast a4b1 is in a highly activated state.
We also demonstrated that the association of CD81 and CD82 with a4b1 was functionally significant, since antibodies to both tetraspanins augmented proerythroblast adhesion to VCAM-1 in the presence of physiological concentrations of Ca 2+ with Mg 2+ . We did not use Mn 2+ in these assays as it has recently been suggested that augmentation effects of tetraspanins on integrin affinity are only evident in systems where conditions are not optimal [38] . There is little evidence for effects of tetraspanin antibodies on the affinity of integrin-mediated adhesion to ligands in static adhesion assays in other cells [29] , or on integrinextracellular matrix protein interactions [37] . Instead, effects are mainly seen in post-ligand binding events, and are evident in integrin-dependent cell spreading, motility and morphology [29, 35, 37] . In this context CD81 enhanced a4b1-mediated adhesion strengthening to stromal cell fibronectin [60] and to VCAM-1 under shear flow [61] . Similarly, CD9 induced pre-B cell adhesion to bone marrow fibroblast-bound fibronectin by upregulating the avidity of a4b1 and a5b1 [62] . Our data suggest that CD81 and CD82 can increase the affinity of a4b1 for VCAM-1 perhaps by promoting receptor clustering. The functional effects of the anti-tetraspanin antibodies suggest that both tetraspanins modulate proerythroblast-macrophage interactions.
Tetraspanin CD151 was also physically and functionally associated with a4b1, irrespective of activation state, in contrast to CD81 and CD82. Different anti-CD151 antibodies also had consistently different functional effects not only on adhesion to VCAM-1, but also to the fibronectin H/120 fragment. Similar to data obtained for tetraspanins CD81 and CD82, the pro-adhesive effect was again evident at the proerythroblast stage of maturation. While the ability of CD151 to regulate integrin-mediated adhesion strengthening in other cells has been extensively studied [35] , this is the first report of an effect on a4b1-mediated adhesion. Our data suggest that tetraspanin CD151 also modulates a4b1-mediated erythroblast binding not only to macrophages, but also to fibronectin, the latter finding also seen in HEL cells [40] . These observations suggest that CD151 could modulate early proerythroblast interactions with several ligands. Indeed, minor effects of CD151 on erythropoiesis have been noted in both CD151-null individuals and one mouse model [51, 63] . CD151 may also be important for megakaryopoiesis since anti-CD151 decreases megakaryocyte progenitor generation in stromal cell cultures [57] . We also observed that tetraspanins CD81, CD82 and CD151 were associated with activated b3 integrins in primary and leukemic erythroblasts, suggesting that these proteins may similarly also modulate early proerythroblast-fibronectin interactions, perhaps affecting erythroid progenitor proliferation and/or differentiation.
We found that the ligand preference for erythroid a4b1 is VCAM-1.H/120.H/0, and this high affinity interaction with VCAM-1 is similar to other hemopoietic cells [64, 65] . The activation states attainable by a4b1 and its ligand profile are cell type-specific and regulated by unknown factors [64] . Moreover, functionally distinct pools of a4b1 exist together in the membrane, the low affinity pool regulating a4b1-mediated adhesion [65] . Several of our observations also suggested a developmentally regulated alteration in ligand binding and in the activation states attainable by a4b1 in erythroid cells ( Figure 5 ). There was a change in adhesion to H/0 and only basophilic erythroblast attachment to H/0 was activated by Mn 2+ , with no effect on proerythroblast or polychromatic stage cells ( Figure 5 ). Similarly the different cations activated basophilic erythroblast attachment to VCAM-1 and H/120 to the same extent, in contrast to the differences seen with these cations on proerythroblast and polychromatic erythroblast attachment. Furthermore, there was a reduced ability of mab 13 to inhibit basophilic erythroblast attachment to H/120 when compared with inhibition of attachment of proerythroblasts and polychromatic erythroblasts ( Figure 6, Figure S6 ). Since mab 13 recognises an epitope that is attenuated by both VCAM-1 and H/120 binding to a4b1 [66] , our results suggest that developmentally regulated changes of basophilic erythroblasts a4b1 increase the ability of H/120 to displace mab 13. Our attachment assays suggest that for proerythroblasts and also perhaps for pre-proerythroblasts, the association of a4b1 with CD81, CD82 and CD151 increases the affinity and/or clustering of a4b1 and promotes erythroblast/ macrophage interactions, in preference to the erythroblast a4b1-fibronectin interaction. An anti-CD151 antibody also augmented erythroblast-fibronectin interactions, suggesting that the association of CD151 with a4b1 can additionally promote proerythroblast-extracellular matrix interactions. Our results demonstrate that tetraspanins can modulate specific a4b1-ligand interactions, in contrast to the reported overall general negative regulation of all erythroblast a4b1 ligand interactions by SWAP-70 [11] . Newham et al., [66] have suggested that as different ligands induce different conformational changes in a4b1, ligand-specific signals can be transduced into the cell. In the context of erythroid cells, this could result in different down-stream signalling events after either fibronectin or VCAM-1 engagement, and may promote the effective erythroblast proliferation and differentiation programme when cells attach to macrophage VCAM-1 and develop within erythroblastic islands. Figure S1 CD151 fluorescence in day 6 erythroblasts. CD151 showed internal fluorescence (green) in day 6 erythroblasts but was negative by fluorescent confocal microscopy as the cells matured (data not shown). (TIF) Figure S2 Several anti-tetraspanin antibodies co-precipitate b1 integrins from HEL cells solubilised in Brij-97. Precipitates were prepared from HEL cells solubilised in different detergents in the presence of Mn 2+ . CD53, MEM-53; CD63, MEM-259; CD81, 454720; CD82, TS82b; CD151, IIG5a; a4, HP2/1; aL, TS1/22; aIIb, PAB-1. Precipitates were run on 7.5% non-reduced gels. (TIF) Figure S3 All anti-CD81, anti-CD82 and anti-CD151 clones co-precipitate b1 and b3 integrins from normal and leukemic proerythroblasts. A. CD81 clones. B. CD82 clones. C. CD151 clones. ERB, day 6 proerythroblasts. a4, HP2/ 1; a5, IIA1; aL, TS1/22; aIIb, PAB-1. Integrins in 7.5% NR gels, tetraspanins in 12% non-reduced gels. More b3 integrins are coprecipitated from HEL cells as they express aIIbb3 and aVb3; proerythroblasts express only aIIbb3. (TIF) Figure S4 Co-precipitation of b1 and b3 integrins by tetraspanins with different cations from HEL cells. Precipitates were prepared from HEL cells solubilised in Brij-97 in the presence of EDTA or cations. b1 is co-precipitated by CD63, CD81, CD82 and CD151 while b3 is co-precipitated by all tetraspanins in the presence of Mn 2+ . CD151 co-precipitates b1 under all conditions. Integrins were separated on 7.5% gels, tetraspanin controls on 12% gels, both non-reducing conditions. CD53, MEM-53; CD63, MEM-259; CD81, 454720; CD82, TS82b; CD151, IIG5a; a4, HP2/1; aL, TS1/22; aIIb, PAB-1. (TIF) Figure S5 Effect of antibodies to b1 and tetraspanins on the binding of erythroblasts to Vascular Cell Adhesion Molecule-1. Box-Whisker plots of normalized values (calculated from the average value of isotype control cells bound) of each data point from all experiments performed at three stages of maturation, with the median, 10 th , 25 th , 75 th and 90 th percentiles depicted as vertical boxes with error bars. *, P,0.001, **, P,0.050; ***, P = 0.051, compared with the relevant isotype control values for each clone as determined by one way analysis of variance (which is a subset of all control values depicted at each time point). All antibodies were tested at each time point at least three times except for CD82 423524 (twice on days 5 and 8, once on day 12) and CD81 1D6 (once on day 12). Coating concentrations of VCAM-1Fc were 0.2 mg/ml, 0.125 mg/ml and 0.25 mg/ml for ProEB, BasoEB and PolyEB, respectively. (TIF) 
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